These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 26380316)

  • 21. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.
    Beeh KM; Kanniess F; Wagner F; Schilder C; Naudts I; Hammann-Haenni A; Willers J; Stocker H; Mueller P; Bachmann MF; Renner WA
    J Allergy Clin Immunol; 2013 Mar; 131(3):866-74. PubMed ID: 23384679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensing of microbial molecular patterns by Toll-like receptors.
    Song DH; Lee JO
    Immunol Rev; 2012 Nov; 250(1):216-29. PubMed ID: 23046132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.
    Kawai T; Akira S
    Immunity; 2011 May; 34(5):637-50. PubMed ID: 21616434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Getting closer to the dirty little secret.
    Pelka K; Latz E
    Immunity; 2011 Apr; 34(4):455-8. PubMed ID: 21511178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of B cell responses by Toll-like receptors.
    Booth J; Wilson H; Jimbo S; Mutwiri G
    Cell Tissue Res; 2011 Jan; 343(1):131-40. PubMed ID: 20824286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TLR-based immune adjuvants.
    Steinhagen F; Kinjo T; Bode C; Klinman DM
    Vaccine; 2011 Apr; 29(17):3341-55. PubMed ID: 20713100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.
    Kawai T; Akira S
    Nat Immunol; 2010 May; 11(5):373-84. PubMed ID: 20404851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics.
    Gomariz RP; Gutiérrez-Cañas I; Arranz A; Carrión M; Juarranz Y; Leceta J; Martínez C
    Curr Pharm Des; 2010; 16(9):1063-80. PubMed ID: 20030612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
    Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N
    J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunostimulatory activity of haptenated proteins.
    Palm NW; Medzhitov R
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4782-7. PubMed ID: 19255434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use and limitations of alum-based models of allergy.
    Eisenbarth SC
    Clin Exp Allergy; 2008 Oct; 38(10):1572-5. PubMed ID: 18644021
    [No Abstract]   [Full Text] [Related]  

  • 32. Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis.
    Bortolatto J; Borducchi E; Rodriguez D; Keller AC; Faquim-Mauro E; Bortoluci KR; Mucida D; Gomes E; Christ A; Schnyder-Candrian S; Schnyder B; Ryffel B; Russo M
    Clin Exp Allergy; 2008 Oct; 38(10):1668-79. PubMed ID: 18631348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine renaissance.
    Almond JW
    Nat Rev Microbiol; 2007 Jul; 5(7):478-81. PubMed ID: 17571456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
    Mata-Haro V; Cekic C; Martin M; Chilton PM; Casella CR; Mitchell TC
    Science; 2007 Jun; 316(5831):1628-32. PubMed ID: 17569868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.
    Gavin AL; Hoebe K; Duong B; Ota T; Martin C; Beutler B; Nemazee D
    Science; 2006 Dec; 314(5807):1936-8. PubMed ID: 17185603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis.
    Creticos PS; Schroeder JT; Hamilton RG; Balcer-Whaley SL; Khattignavong AP; Lindblad R; Li H; Coffman R; Seyfert V; Eiden JJ; Broide D;
    N Engl J Med; 2006 Oct; 355(14):1445-55. PubMed ID: 17021320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toll-dependent selection of microbial antigens for presentation by dendritic cells.
    Blander JM; Medzhitov R
    Nature; 2006 Apr; 440(7085):808-12. PubMed ID: 16489357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of B-cell responses by Toll-like receptors.
    Pasare C; Medzhitov R
    Nature; 2005 Nov; 438(7066):364-8. PubMed ID: 16292312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. (How) do aluminium adjuvants work?
    Brewer JM
    Immunol Lett; 2006 Jan; 102(1):10-5. PubMed ID: 16188325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TLR ligands can activate dendritic cells to provide a MyD88-dependent negative signal for Th2 cell development.
    Sun J; Walsh M; Villarino AV; Cervi L; Hunter CA; Choi Y; Pearce EJ
    J Immunol; 2005 Jan; 174(2):742-51. PubMed ID: 15634894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.